SSRIs + Opioid for Respiratory Insufficiency, Hypercapnia, and Respiratory Depression

"Paroxetine and Oxycodone being tested in this Phase 1 trial are believed to be of low risk, resulting in a score of 1. As such, there is only limited evidence supporting their safety or efficacy."

"Affirmative. Clinicaltrials.gov details that this medical trial, which was initially shared on September 1st 2022, is actively recruiting participants. 25 people need to be recruited from a single location."

"Clinicaltrials.gov shows that this research trial is actively searching for participants, having been first listed on September 1st 2022 and recently modified on October 19th of the same year."

"The goal of this medical study is to measure the Minute ventilation at 55mm Hg end tidal CO2 (VE55) under hyperoxic conditions on day 21 over a 5 hour period. Secondary outcomes include VE55 values for days 11 and 5, as well comparing escitalopram or paroxetine with oxycodone against oxycodone alone on day 12. Regression analysis will be conducted between minute ventilation levels and partial pressure of end tidal CO2 (PETCO2), followed by comparison using linear mixed effects model - all occuring within a five-hour window on each designated date."

"This clinical trial is only available for individuals aged between 18 and 50, as 31 studies are being conducted on those younger than 18, while 164 trials focus on people over 65."

"The clinical trial is inviting 25 persons aged 18-50 with hypercapnia who meet the following criteria to apply: Institutional Review Board (IRB) approved written informed consent, non-smoking status and body mass index of 18.5 - 33.0 kg/m2, standard medical history findings & laboratory results, negative test result for alcohol or drugs of abuse at screening & check-in days, SARS-CoV-2 rapid antigen testing at check-in; female participants must be non childbearing potential confirmed by a follicle stimulating hormone level > 40 mIU/mL or practice two highly effective methods of birth control"